In this special program presented by Touro College & University System, as part of our 50th anniversary celebrations, learn about successful aging, what's new in Alzheimer's research, and the latest advances in detection and treatment.
Welcome
Alan Kadish, M.D.
President, Touro College & University System
Program Introduction
Salomon Amar, D.D.S., Ph.D.
Senior Vice President for Research Affairs, Touro College & University System
Vice President for Research, New York Medical College
Professor of Pharmacology and Microbiology and Immunology, New York Medical College
Professor of Dental Medicine, Touro College of Dental Medicine at NYMC
Program
Moderated By Renee Reijo Pera, Ph.D.
Director, McLaughlin Research Institute
Dean of Research, Touro College of Osteopathic Medicine - Montana Campus (proposed)
What We Have Learned about Alzheimer’s Disease in the Past 50 Years – Where Do We Go Now?
Michael L. Shelanski, M.D., Ph.D.
Henry Taub Professor of Pathology and Cell Biology
Co-Director of the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain
Senior Vice Dean for Research
College of Physicians and Surgeons, Columbia University
Following A Dog's Path to Aging Successfully
Edward (Ted) G. Barrett, Ph.D.
Senior Director, Pharmacology and Translational Science, Lovelace Biomedical
Accelerating Alzheimer's and Dementia Research: Scientific Advances in Early Detection and Treatment
Rebecca Edelmayer, Ph.D.
Senior Director, Scientific Engagement, Medical & Scientific Relations, Alzheimer’s Association
How Science and Culture Turned This Rare Disease into a Very Common One
Jason Karlawish, M.D.
Professor of Medicine, Medical Ethics and Health Policy, and Neurology, University of Pennsylvania Perelman School of Medicine
Co-Director, Penn Memory Center
Director, Penn Healthy Brain Research Center
Director, Outreach, Recruitment, and Retention Core of the Penn Alzheimer’s Disease Research Center
Q&A
Facilitated by Edward Halperin, M.D., M.A.
Chancellor and Chief Executive Officer, New York Medical College
Provost for Biomedical Affairs, Touro College & University System
You can send in questions for the Q&A in advance to conf.questions@touro.edu
Michael L. Shelanski, M.D., Ph.D.
Dr. Michael Shelanski is a cell biologist and neuropathologist. He received his MD and PhD degrees from the University of Chicago and trained in Neuropathology with Alzheimer’s Disease pioneer, Robert Terry, at Albert Einstein where he served as Assistant Professor of Pathology. Subsequently, he worked in the laboratories of Nobel Laureate Marshall Nirenberg at the NIH and Jean-Pierre Changeux at the Institute Pasteur. He was Associate Professor of Neuropathology at Harvard prior to assuming the Chair of Pharmacology at NYU in 1978. In 1987 he moved to Columbia as the Delafield Professor and Chairman of the Department of Pathology and Cell Biology. Together with Dr. Richard Mayeux he founded the NIH-sponsored Alzheimer’s Disease Research Center at Columbia and served as its Director for almost 25 years. He also served as Director of the Medical Scientist Training Programs at both NYU and Columbia. He is a member of numerous advisory and editorial boards and a member of the National Academy of Medicine and of the Association of American Physicians. In 2015, he was appointed Senior Vice Dean for Research and the Henry Taub Professor of Pathology and Cell Biology. He and Dr. Mayeux have shared the Directorship of the Taub Institute since its founding.
Dr. Shelanski’s pioneering work on identification and purification of tubulin (with E. W. Taylor) and the purification and characterization of the neurofilament proteins (with Ron Liem) are the key elements in our understanding of how cells make and keep their shape and organize their internal functions. His laboratory led in the development of methods for purification of tubulin and associated proteins; the localization and primary structure of high molecular weight tau protein; the development of the concept of multiple parallel paths to cell death depending on the type of injury to the cell and studies on the role of the cAMP/PKA/CREB system in A regulation of synaptic plasticity. He has worked on the possible role of endogenous stem cells in Alzheimer’s disease and on the application of systems biology to neurodegenerations.
The Shelanski laboratory has trained many leaders in neurodegeneration including Virginia Lee (Pennsylvania), Denis Selkoe (Harvard), Shu-Hui Yen,(Mayo), Ron Liem (Columbia) and Rajiv Ratan (Cornell). During his time at Columbia he has recruited key researchers in Cancer Biology, Neurobiology and Cell Biology, including 5 who have been elected to the US National Academy of Sciences and two more to the National Academy of Medicine.
Dr. Shelanski has served as a member of numerous Study Sections at the NIH as well as study sections at the ACS, Alzheimer’s Association, ALS Association, and the Dystonia Association. From 1981-1987 he chaired the New York State Overhead Power Lines Advisory Committee which, under his leadership, established a competitive, investigator-initiated grants program to evaluate the presumptive environmental risk from high voltage AC power transmission. He also served on the Committee on Non-ionizing Radiation of the National Research Council in 1986. He has continued his involvement in issues of science and the public during service on the Board of Directors of the Alzheimer’s Association, the Board of Trustees of the Presbyterian Hospital and corporate scientific advisory boards. He has been a member of the scientific advisory boards of the Alzheimer’s Disease Research Centers at Harvard, Johns Hopkins, USC-Irvine, UCSD, and the University of Minnesota, as well as the Scientific Advisory Board for the Advanced Practice Nursing Study at the Columbia University School of Nursing. He has served on the editorial boards of the J. Mechanochemistry and Cell Motility, the Neurobiology of Aging, Laboratory Investigation, the Journal of Neuropathology and Experimental Neurology, Brain Pathology, Neuroscience and the Journal of Neuroscience. He is the Past- President of the Scientific Advisory Board of the Institut du Cerveau (Paris Brain Institute) in France.
Edward (Ted) G. Barrett, Ph.D.
Ted Barrett, Ph.D., is Senior Director, Pharmacology and Translational Science at Lovelace Biomedical. He was educated at the University of Colorado and University of Rochester and joined Lovelace in 1999. Dr. Barrett has spent most of his career investigating the effects of small molecule, biologic, nucleic acid and medical device technologies in various cell and animal models of disease ranging from Asthma-Allergy to Alzheimer’s. His collaborations with industry and academia have resulted in numerous breakthroughs in understanding the biology of disease that have ultimately been translated to the patient in need. His programs aim to translate nonclinical efficacy, pharmacokinetic, and pharmacodynamic data to the human clinical paradigm to support novel treatments.
Rebecca Edelmayer, Ph.D.
As senior director, Scientific Engagement for the Alzheimer’s Association®, Dr. Edelmayer leads efforts to accelerate the organization’s scientific agenda through the creation and delivery of ongoing research education. She engages with more than 75 Association chapters across the country, ensuring that communities are informed of the global progress of dementia science and the organization’s crucial role in advancing research to improve the lives of those facing Alzheimer’s and all other dementia.
Edelmayer has lectured, published and led collaborations in areas of neurodegenerative disease, neurophysiology, inflammatory skin pathology and pain neurobiology. She completed her Ph.D. and postdoctoral training in medical pharmacology with a focus on neuropharmacology at the University of Arizona College of Medicine. Dr. Edelmayer holds a bachelor’s degree in neuroscience from the University of Pittsburgh, where she also completed a National Institute of Mental Health research fellowship.
Jason Karlawish, M.D.
Dr. Jason Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania Perelman School of Medicine. He is board-certified in geriatric medicine. He was educated at Northwestern University, the Johns Hopkins Medical Institutions and the University of Chicago.
Dr. Karlawish is a Senior Fellow of the Leonard Davis Institute of Health Economics, Senior Fellow of the Penn Center for Public Health Initiatives, fellow of the University of Pennsylvania’s Institute on Aging, director of the Penn Program on Precision Medicine for the Brain (P3MB), Co-Associate Director of the Alzheimer’s Disease Research Center, and co-director of the Penn Memory Center. He is also director of the Alzheimer’s Disease Research Center’s Outreach, Recruitment and Education Core and the center’s Research Education Component.
His research focuses on aging, neuroethics and policy. He has investigated issues in dementia drug development, informed consent, quality of life, paradoxical lucidity and theory of mind in dementia, research and treatment decision-making, and voting by persons living with dementia. He is the project leader of makingsenseofalzheimers.org, a creative space for understanding the past, present and future of Alzheimer’s disease. He is the author of The Problem of Alzheimer’s: How Science, Culture and Politics Turned a Rare Disease Into a Crisis and What We Can Do About It, and the novel Open Wound: The Tragic Obsession of Dr. William Beaumont. His essays on ethics and aging have appeared in The Hill, The New York Times, Philadelphia Inquirer, STATnews and The Washington Post.
To learn more about his research and writing, visit www.jasonkarlawish.com.
This meeting has been approved for 1.5 CME credits by the Office of Continuing Medical Education, New York Medical College free of charge as a community service to our Healthcare Providers.
Accreditation Statement:
New York Medical College is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Target Audience:
Hospital-based physicians; Community physicians; Nurses; Pharmacists; Medical Students; Residents/Fellows; Public Health; Other Healthcare Providers; and Press.
Credit Designation:
The New York Medical College designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Statement:
All activity faculty and planners participating in continuing medical education activities provided by New York Medical College are expected to disclose to the audience any significant support or substantial relationship(s) with commercial entities whose products are discussed in their presentation and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentations.
Commercial Support:
There is no outside funding for this activity.